Elsewhere in this issue Kempe and collaborators report on numerous negative findings in the evaluation of Reticulose in a number of virus infections of animal and man. The questions raised by these studies are serious ones indeed. Here is an injectable product widely detailed throughout the country, particularly to general practitioners and pediatricians in rural and smaller urban areas, widely advertised in certain journals, but not in the principal pediatric journals, which claims to be the "first antiviral biotic of proven clinical results."
On the face of it, it would be amazing that a substance which has been available since 1938 and which was used in its early days for nonspecific protein therapy should require resurrection in 1957 as an antiviral substance. The advertising to physicians states that "clinical improvement objectively and subjectively may be anticipated within 24 to 36 hours." The list of diseases "successfully treated" covers the entire